At a glance
- Cells are collected, engineered off-site, then reinfused.
- Requires close monitoring; not delivered as routine day-care.
- Suitability is decided by a multidisciplinary tumour board.
What CAR-T is
Chimeric antigen receptor T-cell (CAR-T) therapy is a living drug. T-cells are collected from your blood, genetically engineered in a laboratory to carry a receptor that recognises a protein on the cancer cell (such as CD19), multiplied, and infused back. The engineered cells then hunt the cancer.
Who it is for
CAR-T is approved for certain relapsed or refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia and multiple myeloma. Indian-manufactured CAR-T products have made the therapy considerably more accessible.
Access through Shichim
CAR-T requires close inpatient monitoring for cytokine release syndrome and neurological effects, so it is not delivered as routine day-care. Shichim Oncocare assesses suitability through its tumour board, coordinates the cell collection and infusion with a partner CAR-T centre, and provides pre- and post-therapy care at the day-care centre.